SCHEMBL2991610

SCHEMBL2991610

O=C(CCl)Nc1ccc(Cl)cc1C(=O)c1ccccc1Cl

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.78
GABRD O14764 2/20 0.78
GABRA1 P14867 2/20 0.78
GABRB1 P18505 2/20 0.78
GABRG2 P18507 2/20 0.78
GABRB3 P28472 2/20 0.78
GABRA5 P31644 2/20 0.78
GABRA3 P34903 2/20 0.78
GABRA2 P47869 2/20 0.78
GABRB2 P47870 2/20 0.78
GABRA4 P48169 2/20 0.78
GABRE P78334 2/20 0.78
GABRA6 Q16445 2/20 0.78
GABRG1 Q8N1C3 2/20 0.78
GABRG3 Q99928 2/20 0.78
GABRQ Q9UN88 2/20 0.78
CYP1A2 P05177 3/20 0.60
CYP2C19 P33261 2/20 0.60
MAPT P10636 6/20 0.60
ALDH1A1 P00352 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7936060 0.88 GABRP (0.76) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL11061295 0.88 GABRP (1.00) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL10813064 0.88 GABRP (0.76) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL11870764 0.86 GABRP (0.60) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15314665 0.86 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30661080 0.84 ALDH1A1 (0.71) CYP1A2CYP2C19MAPTALDH1A1LMNA
SCHEMBL16922182 0.84 ALDH1A1 (0.71) CYP1A2CYP2C19MAPTALDH1A1LMNA
SCHEMBL5418944 0.84 ALDH1A1 (0.71) CYP1A2CYP2C19MAPTALDH1A1LMNA
SCHEMBL11824528 0.84 GABRP (0.71) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2987985 0.83 CYP1A2 (0.71) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142506-B1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2013-10-16 EP claimed
US-8394954-B2 Benzophenone hybrids as anticancer agents and processes for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-03-12 US claimed
US-20100174074-A1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-07-08 US claimed
EP-2142506-A1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF Council of Scientific&Industrial Research (IN) 2010-01-13 EP claimed
WO-2008120235-A1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2008-10-09 WO claimed
EP-2061795-B1 PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2014-01-15 EP disclosed
EP-2142506-B1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2013-10-16 EP disclosed
EP-2142506-B1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2013-10-16 EP disclosed
US-8394954-B2 Benzophenone hybrids as anticancer agents and processes for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-03-12 US disclosed
US-8394954-B2 Benzophenone hybrids as anticancer agents and processes for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-03-12 US disclosed
US-8394954-B2 Benzophenone hybrids as anticancer agents and processes for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-03-12 US disclosed
US-20120128768-A1 ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY LABORATORIOS DEL DR. ESTEVE S.A (ES) 2012-05-24 US disclosed
US-5091415-A Antiulcer, antisecretory agents PIERRE FABRE MEDICAMENT (FR) 1992-02-25 US disclosed
US-5075488-A Fungicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-12-24 US disclosed
EP-0128006-B1 A SOIL-DISEASE-CONTROLLING AGENT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-09-18 EP disclosed
US-5025015-A Antisecretory and antiulcer agents PIERRE FABRE MEDICAMENT (FR) 1991-06-18 US disclosed
US-4709052-A FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-11-24 US disclosed
EP-0143016-B1 DERIVATIVES OF 4-(3-ALKYNYLOXY-2-HYDROXY-PROPYL)-PIPERAZIN-1-YL-N-PHENYL ACETAMIDE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE RIOM LABORATOIRES- C.E.R.M. "R.L.-CERM" - (S.A.) (FR) 1987-07-29 EP disclosed
EP-0143016-A1 Derivatives of 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-N-phenyl acetamide, their preparation and their therapeutical use RIOM LABORATOIRES- C.E.R.M. "R.L.-CERM" - (S.A.) (FR) 1985-05-29 EP disclosed
EP-0128006-A2 A soil-disease-controlling agent SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174074-A1 NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF TP53, RB1, MCL1 GABRP 2355/4885GABRD 3476/4885GABRA1 2940/4885
US-20120128768-A1 ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY HTR6, NPY5R, NPY2R GABRP 191/4885GABRD 340/4885GABRA1 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.